LACERO
9.6.2020 09:02:08 CEST | Business Wire | Press release
Lacero, a next generation governance technology provider for digital assets, today announced the launch of FlowOS, offering advanced transaction control and permissioning. FlowOS is now live with major cryptocurrency liquidity provider B2C2.
FlowOS enhances existing wallet and custody solutions, giving users direct, independent control of their policies, procedures and rules. A radically different solution, it is the first platform to leverage blockchain technology to create a decentralised, immutable security architecture by constructing policy from independently certified smart contracts.
Introducing real-time governance, traceability and auditability, it makes it impossible to substitute, manipulate or circumvent approved policies and procedures, and enables reliable exception-based processing with a combination of programmable rules, automated workflow procedures and human approvals.
B2C2 has selected Lacero for its best-in-class technology for governance, controls and procedures. B2C2’s integration of FlowOS, in combination with its existing integration of Fireblocks’ cutting-edge payments technology, will further enhance the firm’s settlement capabilities – the largest by some margin in the OTC markets – for the benefit of its clients.
This combination of technology platforms further demonstrates B2C2’s bank-grade security and compliance standards which, twinned with its award-winning technology and the tightest and most consistent pricing, has made it the OTC liquidity provider of choice to the largest institutional names in the industry.
B2C2’s settlement platform, enhanced by the decentralised, auditable solutions offered by Lacero and Fireblocks, is setting a market standard for straight-through-processing that is applicable to both cryptocurrency and traditional financial markets.
Rashid Hoosenally, CEO of Lacero, said: “We’re excited to be partnering with a proven industry leader who shares our vision for institutional-grade governance and controls. B2C2 strive to continuously optimise processes and tailor workflows, so we’re delighted that FlowOS has been selected to provide them with a secure, flexible enforcement platform that can support them as they grow the scale, speed and breadth of their offering.”
Max Boonen, Founder and Group CEO of B2C2, said: “B2C2’s mission to bring best practices to the trading of digital assets spans both execution and post-trade. The ability to streamline and automate both trading and settlement is the next frontier in our industry. Enhancing the B2C2 platform with Lacero’s innovative technology will allow us to better serve our clients and further scale our business as the go-to counterparty.”
Simon Heinrich, CIO and Group Head of Technology at B2C2, said: “Operational excellence and client service are at the heart of what we do at B2C2 as we are relied upon to provide institutional-grade liquidity 24/7. Given the trustless environment and irreversibility of transactions in the continuously traded and settled crypto markets, FlowOS represents a critical component of our offering as it enables controlled autonomy of our processes in a demonstrably secure way.”
-Ends-
About Lacero
Lacero develops innovative technology for governing and safeguarding digital assets and data. Its platform is underpinned by blockchain, certified smart contracts and highly secure cryptographic methods. Based in the UK, Lacero was awarded Best RegTech Policy Platform 2020
in Wealth and Finance International’s FinTech Awards. For more information on Lacero’s FlowOS platform, please visit https://www.lacero.io
About B2C2
Founded in 2015, B2C2 is the leading cryptocurrency liquidity provider. Awarded Cryptocurrency Innovation of the Year
in 2020 by FStech and Best Institutional Crypto Liquidity Provider
in 2019 by the readers of Profit & Loss, B2C2 bridges the gap between traditional financial and cryptocurrency markets. The company is trusted by brokerages, exchanges, banks and fund managers to provide 24/7 liquidity. Headquartered in the UK, with offices in London, Jersey City and Tokyo, the firm is privately held. For more information, please visit https://www.b2c2.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom